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Abstract
Purpose—Cross-talk and feedback between the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR 
cell signaling pathways is critical for tumor initiation, maintenance, and adaptive resistance to 
targeted therapy in a variety of solid tumors. Combined blockade of these pathways—horizontal 
blockade—is a promising therapeutic strategy; however, compounded dose-limiting toxicity of 
free small molecule inhibitor combinations is a significant barrier to its clinical application.
Experimental Design—AZD6244 (selumetinib), an allosteric inhibitor of Mek1/2, and PX-866, 
a covalent inhibitor of PI3K, were co-encapsulated in a tumor-targeting nanoscale drug 
formulation—layer-by-layer (LbL) nanoparticles. Structure, size, and surface charge of the 
nanoscale formulations were characterized, in addition to in vitro cell entry, synergistic cell 
killing, and combined signal blockade. In vivo tumor targeting and therapy was investigated in 
breast tumor xenograft-bearing NCR nude mice by live animal fluorescence/bioluminescence 
imaging, Western blotting, serum cytokine analysis, and immunohistochemistry.
Results—Combined MAPK and PI3K axis blockade from the nanoscale formulations (160 ± 20 
nm, −40 ± 1 mV) was synergistically toxic toward triple-negative breast (MDA-MB-231) and 
RAS-mutant lung tumor cells (KP7B) in vitro, effects that were further enhanced upon 
encapsulation. In vivo, systemically administered LbL nanoparticles preferentially targeted 
subcutaneous MDA-MB-231 tumor xenografts, simultaneously blocked tumor-specific 
phosphorylation of the terminal kinases Erk and Akt, and elicited significant disease stabilization 
in the absence of dose-limiting hepatotoxic effects observed from the free drug combination. Mice 
receiving untargeted, but dual drug-loaded nanoparticles exhibited progressive disease.
Conclusions—Tumor-targeting nanoscale drug formulations could provide a more safe and 
effective means to synergistically block MAPK and PI3K in the clinic.
Introduction
Combination chemotherapy has been a mainstay of clinical oncology since the mid 1960s 
(1, 2). While initially proposed to exploit nonoverlapping toxicity profiles of cytotoxic 
chemotherapeutics, recent advances in cancer cell signaling and the discovery of potent and 
selective small-molecule inhibitors have led to the development of rational combination 
approaches to cancer chemotherapy. These strategies can prime cancer cells for apoptosis (3, 
4), abrogate mechanisms for resistance (5–9), block cancer cell-cycle progression (10), or 
dynamically rewire DNA damage response pathways (11, 12)—all leading to enhanced 
tumor cell killing.
Although combination therapies can be curative in a subset of malignancies (13), inefficient 
delivery limits the safety and efficacy of cooperative drug combinations that require cellular 
colocalization for effective cell killing. This can be difficult to achieve with traditional 
pharmaceutical excipients as synergistic compounds often exhibit vastly different 
physiochemical properties (e.g., size, charge, lipophilicity, and stability) that necessitate 
separate drug carriers. Colocalized delivery of cooperative drug combinations from single, 
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multicomponent delivery vehicles can improve both therapeutic index (5) and treatment 
outcomes (6, 9, 12, 14) compared with combinations of individual carriers; however, tissue-
specific delivery remains a significant challenge. Nanoscale drug carriers that deliver 
cooperative drug combinations in a tumor-targeted fashion are urgently needed in the clinic.
Layer-by-layer (LbL) nanoparticles (15–24) are a new class of self-assembled polymer drug 
carriers that addresses challenges in the delivery of combination therapeutics. These 
structures consist of a functional nanoparticle core, a polyelectrolyte multilayer shell, and an 
exterior tumor-targeting stealth layer. Previously, we developed an LbL nanoparticle 
architecture that targets solid tumors through 3 independent mechanisms: (i) size-dependent 
passive tumor targeting, (ii) active, ligand-directed targeting of cell surface CD44 receptor, 
and (iii) hypoxic tumor pH-responsive cellular delivery (24). Here, we apply multimodal 
tumor-targeting LbL nanoparticles to drug solid tumors with a synergistic combination of 
small-molecule inhibitors that block known resistance pathways to MAPK and PI3K axis 
therapies.
The MAPK (RAS/RAF/MEK/ERK; ref. 25) and PI3K/AKT/mTOR (26) pathways are 
among the most frequently deregulated cell signaling pathways in human cancer. Activating 
mutations in RAS and BRAF are observed in 20% to 30% and 8% of human tumors, 
respectively (27–29), with PTEN and PIK3CA mutations occurring in 30% to 50% and 4% 
to 32%, respectively (30, 31). Aberrant activation of either pathway is capable of 
transforming cells in vivo in the appropriate genetic mutant background (32, 33), and the co-
existence of mutations along both pathways is approximately twice as prevalent among 
advanced solid tumors (34). Although various proteins or upstream effectors of these signal 
cascades are clinically druggable (e.g., receptor tyrosine kinases, BRAF, MEK, PI3K, Akt, 
and mTOR), durable responses to molecularly targeted therapies has been difficult to 
achieve, due in part to extensive cross-talk and compensatory feedback between MAPK and 
PI3K signaling pathways (35). Upregulated MAPK signaling, for example, has been 
implicated in adaptive resistance to PI3K (36), Akt (37), and mTOR (38) inhibitors. 
Conversely, augmented PI3K signaling has been shown to contribute to resistance toward 
EGFR (39), BRAF (40), and MEK (41) inhibitors. PI3K signaling is also known to predicate 
maintenance of RAS-dependent lung tumors (33, 42), and cross-talk between these 2 
pathways is known to be required for RAS-dependent angiogenesis (43).
Horizontal blockade of MAPK and PI3K has been proposed as a means to achieve 
synergistic cell killing and to abrogate adaptive resistance to single-axis targeted therapies. 
Engelman and colleagues found that combined MEK and PI3K/mTOR inhibition was 
synergistic against genetically engineered mouse models of KRAS-mutant non-small cell 
lung cancer (33). Similarly, Posch and colleagues reported that that dual inhibition of MEK 
and PI3K/mTOR was both synergistic and required for durable treatment response in 
NRAS-mutant melanoma in vitro and in vivo (44). A recent phase I clinical trial 
investigating simultaneous (i.e., horizontal) blockade of MAPK and PI3K in patients with 
refractory solid tumors found that dual inhibition may exhibit favorable efficacy compared 
with single-axis therapy, albeit with compounded and often dose-limiting toxicity (45). 
Here, we address this unmet clinical need by engineering nanoscale drug carriers that 
improve the therapeutic index of this novel combination therapy through multimodal 
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targeted delivery to solid tumors. These modular, dual drug-containing delivery vehicles 
horizontally block MAPK and PI3K signaling to diminish tumor growth in vivo. 
Nanotechnology-enabled horizontal blockade of MAPK and PI3K is a promising strategy 
for the treatment of several solid tumor types and is demonstrated here in triple-negative 
breast cancer tumor models.
Materials and Methods
Materials
Poly(L-lysine) HBr (PLL, 15-30 kDa; Sigma-Aldrich), hyaluronan (HA, 200 kDa; Lifecore), 
and dextran sulfate sodium salt (DXS, 20 kDa; Sigma-Aldrich) were used as-received 
without further modification. Antibodies included total Akt (CST 4691), cleaved caspase-3 
(CST 9661), total Erk (CST 4370), pAkt (CST 4060; S473), pAkt-Alexa Fluor 488 
(Millipore CS203310; S473), pErk1/2 (CST 4370; T202/204, T185/187), and pErk1/2-PE 
(Millipore CS203329; T202/204, T185/187).
Nanoparticle synthesis and characterization
LbL nanoparticle assembly was performed as described previously (24). Liposomes were 
prepared by the sonication/extrusion method. Briefly, a chloroform mixture of DOTAP/
DOPE/cholesterol (35:35:30 mol ratio, Avanti) was dried under nitrogen and stored 
overnight under vacuum. The lipid film was hydrated with a PBS solution of AZD6244 
(Selleck) and PX-866 (LC Laboratories) at 18 wt%, each and immersed in a bath sonicator 
(55 °C) for 1 hour. The crude liposomes were extruded through a 50-nm polycarbonate 
membrane syringe extruder (Avanti) at 55°C, dialyzed against PBS for 48 hours (3.5-5 
MWCO), and stored at 4°C for <1 week before use. Drug loading was quantified by HPLC 
(Agilent Technologies) in 50:50 acetonitrile/water (pH 5). Cryogenic transmission electron 
microscopy (TEM) was performed using a JEOL 2100 FEG instrument. Photon correlation 
spectroscopy and laser Doppler electrophoresis measurements were carried out using a 
Malvern Zetasizer Nano ZS90 particle analyser (λ = 633 nm, material/dispersant RI 
1.590/1.330). Chemical properties were computed using ACD/Labs software (pH 7.4).
Cell culture
OVCAR-3, Hep G2, and MDA-MB-231 cells were obtained from ATCC Murine KP7B 
cells were a gift from the laboratory of Tyler Jacks (46); these cells were obtained from the 
murine KP model of lung adenocarcinoma (KrasLSL-G12D/wt;p53flox/flox) that exhibits 
conditional activation of oncogenic Ras. Cells were subcultured in DMEM supplanted with 
10% FBS and penicillin/streptomycin or the supplier's recommended basal medium in a 5% 
CO2 humidified atmosphere.
In vitro experiments
Viability was assessed by CellTiter-Glo assay (Promega) and normalized to vehicle controls. 
The Bliss expectation was calculated as (A + B) − (A × B), in which A and B are the 
fractional growth inhibitions induced by agents A and B at a given dose, respectively (47). 
Signaling was assessed in MDA-MB-231 cells serum-starved for 24 hours and then treated 
with drugs and/or particles and serum-stimulated (10% v/v FBS) for the times indicated. 
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Cells were analyzed by flow cytometry or scraped, pelleted, and lysed in RIPA buffer 
containing protease/phosphatase inhibitor for Western blotting. Densitometry was calculated 
using ImageJ software. Statistical significance was assessed by the unpaired Student t test.
Fluorescence imaging
Hep G2 tumor spheroids (low CD44 expression) were prepared as described previously (24) 
and incubated for 3 hours in PBS containing 0.17 nmol/L LbL nanoparticles. Tumor 
spheroids were fixed in 3.7% paraformaldehyde for 30 minutes at room temperature, 
permeabilized with 0.1% Triton X-100 (PBS) for 5 minutes at room temperature, stained 
with Alexa Fluor 568 phalloidin (Life Technologies) for 30 minutes at room temperature, 
and inverted/mounted with Fluoromount onto 35-mm MatTek dishes. Fluorescent 
carboxylate-modified polystyrene beads (100 nm; Sigma-Aldrich; Orange 481/644) were 
substituted for dextran sulfate-layered liposomes to facilitate visualization of cellular 
localization. Slides were mounted and imaged using a Nikon 1AR Ultra-Fast Spectral 
Scanning Confocal Microscope.
Flow cytometry
Endocytotic inhibition was assessed using a BD LSR II flow cytometer following 1-hour 
preincubation in complete growth media supplanted with 10 mmol/L sodium azide/50 
mmol/L 2-deoxy-D-glycose (ATP inhibition), 200 μmol/L genistein (caveolin inhibition), 10 
μmol/L chlorpromazine (clathrin inhibition), 10 μmol/L wortmannin (macropinocytosis 
inhibition), 5 mmol/L methyl β-cyclodextrin (caveolin- and clathrin-independent inhibition; 
DMSO ≤ 0.5%v/v), and 1-hour co-incubation in complete growth medium supplanted with 
inhibitors and 0.1 nmol/L LbL nanoparticles (561 nm ex; 610/20 nm em). 
Immunofluorescence cytometry was performed using the FlowCellect Pathway Activation 
Kit (Millipore FCCS025100) and 100-nm fluorescent carboxylate-modified polystyrene 
beads (Life Technologies; Red 580/605) were used as surrogates for dextran sulfate-
conjugated liposomes.
In vivo cytokine response
Hyaluronan-or dextran sulfate-LbL nanoparticles (8.3 × 1012 NP/kg, 5% glucose) were 
injected via the tail vein into 6- to 8-week-old female BALB/c mice (n = 3). Blood was 
withdrawn at 1 and 6 hours postinjection via retro-orbital bleed and 24 hours postinjection 
via cardiac puncture, into serum separator tubes (1,000 rcf, 4°C; GreinerBio) and stored at 
−20°C until use. Serum was analyzed via magnetic bead-based multiplexed immunoassay 
(BioRad BioPlex 3D; 8-Plex Cytokine Panel) using a BIO-RAD Bio-Plex 3D Suspension 
Array System.
In vivo experiments
A total of 5 × 106 MDA-MB-231 cells (1:1 PBS:Matrigel) were injected subcutaneously 
into the hindflanks of nude mice (NCR nu/nu, Taconic). Tumors were allowed to form over 
3 to 4 weeks, after which treatment groups were randomized. Nanoparticles (8.3 × 1012 
NP/kg, 5%glucose) were injected via the tail vein into tumor-bearing nude or 
immunocompetent mice (BALB/c, Taconic). Whole-animal imaging was performed using a 
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Xenogen IVIS Imaging System (Caliper) and 100-nm fluorescent carboxylate-modified 
polystyrene beads (Life Technologies; Infrared 715/755) as surrogates for dextran sulfate-
conjugated liposomes. Free drugs were dosed o.g. at nanoparticle-equivalent drug 
concentrations (5% D-glucose, 1% polysorbate 80). Albumin, blood urea nitrogen (BUN), 
and creatinine (Cr) levels were measured by Charles River Laboratories from serum samples 
obtained via cardiac puncture 24 hours following nanoparticle (i.v.) or free drug (o.g.) 
administration in 6- to 8-week-old female BALC/c mice. These experiments were approved 
by the Massachusetts Institute of Technology Committee on Animal Care (CAC).
Histology
Hepatic lesion scores (48) were assigned as follows: grade 0, no evidence of histologic 
lesions; 1, minimal congestion and mild hepatocellular cytoplasmic degeneration 
immediately adjacent to the central vein; 2, moderate congestion and degeneration with 
individual necrotic hepatocytes in the periportal region; 3, marked congestion and 
degeneration with necrotic hepatocytes extending into the midzonal regions; 4, severe 
congestion and degeneration and necrosis that bridges between most centrilobular zones. 
Tissue samples were obtained at 24 hours following nanoparticle (i.v.) or free drug (o.g.) 
administration in 6- to 8-week-old female BALC/c or NCR nude mice for toxicologic or 
pharmacodynamics analysis, respectively. Tumors were lysed in RIPA buffer containing 
protease/phosphatase inhibitor and analyzed by Western blotting. Vital organs were 
formalin-fixed, paraffin-embedded, and processed by the Swanson Biotechnology Center 
(MIT).
Results
We selected AZD6244 (selumetinib), an allosteric inhibitor of Mek1/2, and PX-866, a 
wortmannin analogue and covalent inhibitor of PI3K, for their potent activity against MAPK 
oncogene-addicted solid tumors (33, 49, 50). Interestingly, AZD6244 (logD ∼ 5.55) and 
PX-866 (logD ∼ 2.26) exhibit vastly differing lipophilicities and would thus be challenging 
to entrap within a single polymer nanoparticle matrix such as poly(lactic acid-co-glycolic 
acid) (PLGA). Here, the 2 drugs were encapsulated by sonication/extrusion within cationic 
vesicles (90 ± 11 nm dia) composed of DOTAP with DOPE helper phospholipid (Fig. 1A 
and B). Polyelectrolyte multilayers were then self-assembled onto the drug-containing 
vesicle cores by alternating adsorption and centrifugation (24). The strongly ionized 
polyelectrolyte, dextran sulfate, was used to initially stabilize the carriers and impart anionic 
charge. Next, a hypoxic tumor pH-responsive and CD44 receptor-targeting bilayer of poly-
(L-lysine) and hyaluronic acid were assembled onto the nanoparticles. Previously (24), we 
found that this architecture was capable of actively targeting the cancer stem cell marker, 
CD44, through hyaluronan binding and also selectively underwent a transition in surface 
charge and swelling at pH values <7, leading to both size-dependent passive tumor targeting 
and active targeting through both ligand-directed and hypoxic pH-responsive delivery.
Layer-by-layer assembly onto the drug-loaded particle cores yielded 160 ± 20 nm dia 
nanoparticle drug carriers as the final product (Fig. 1B and C; 2.7 wt% AZD6244, 10 wt% 
PX-866). Hydrodynamic size evolution during the LbL self-assembly process was 
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monitored by cryogenic-transmission electron microscopy (cryo-TEM, Fig. 1B), dynamic 
light scattering (Fig. 1C), and laser Doppler electrophoresis (Fig. 1D), indicating size 
increase and corresponding charge shift with each successive layer. In addition to its tumor 
targeting capabilities (24), the LbL architecture was also used to decrease nonspecific drug 
leakage from the particles (51). In vitro, fluorescent LbL nanoparticles penetrated 3-
dimensional (3D) tumor spheroids with high efficiency (Fig. 1E), likely a result of the 
highly hydrated, anionic, and protein-repellent outer hyaluronan shell (24). The particles 
also exhibited cell uptake through ATP-dependent mechanisms including clathrin-mediated, 
macropinocytotic, and cholesterol-mediated processes (Fig. 1F) as assessed by flow 
cytometry. In agreement with previous reports investigating cellular interactions with 
hyaluronan-conjugated nanoparticles, we found that LbL nanoparticle uptake here was 
partially mediated by interactions with lipid rafts (52), as indicated by a 32% loss in uptake 
following cholesterol depletion using methyl-β-cyclodextrin. We also observe contributions 
from clathrin-mediated and micropinocytosis processes which have also been implicated in 
the cellular uptake of free hyaluronan (53).
We additionally investigated combinatorial interactions between Mek and PI3K blockade 
using free drugs in vitro, as measured by the amount of (synergistic) cell killing in excess of 
the additive Bliss expectation (47; 48 hours, see Materials and Methods for details). 
Horizontal blockade was synergistic in triple-negative breast (MDA-MB-231) and murine-
derived Ras-mutant non–small cell lung carcinoma (Fig. 2A), but interestingly, not in an 
epithelial ovarian cancer cell line (OVCAR3; Supplementary Fig. S1), in agreement with 
that cell line's lack of MAPK/PI3K mutations that predicate response (e.g., activating 
mutations in Ras, BRAF, or PI3K; loss of PTEN; ref. 54). These results are also in 
agreement with Hoeflich and colleagues (55) and Iadevaia and colleagues (56) who 
predicted synergistic cell killing of basal-like (triple-negative) breast carcinoma following 
dual blockade of MAPK and PI3K. Likewise, Engelman and colleagues (33) demonstrated 
that combined pathway signaling is required for Ras-dependent tumor initiation, whereas 
Downward and colleagues found that dual pathway activation is required for Ras-dependent 
tumor maintenance (42) and angiogenesis (43). Interestingly, LbL nanoparticle 
encapsulation further improved synergistic cell killing in MDA-MB-231 cells by 2.6-fold, 
consistent with simultaneous blockade of pErk1/2 and pAkt staining as measured by 
immunofluorescence cytometry (Fig. 2B and C). While studies are currently under way to 
elucidate the precise mechanism of nanoparticle-enhanced drug synergy, the results here 
may result from nanoparticle-accelerated or -augmented intracellular transport or 
simultaneous intracellular delivery of the hydrophobic–hydrophilic drug pair. Delivery of 
the 2 drugs, directly, may also lead to differential cell uptake for the drug pair that have 
notably disparate physiochemical properties. Kinetics of uptake and release may also be a 
factor. Interestingly, we found that at early time points (10-minute serum stimulation 
following 1 hour of drug treatment), nanoparticle inhibition of pAkt was more complete than 
from equivalent concentrations of the free drug combination (Fig. 2D), potentially 
abrogating PI3K pathway-mediated apoptotic suppression, at minimum (57). Using an in 
vivo mouse model, LbL nanoparticles targeted subcutaneous, CD44-expressing, triple-
negative breast (MDA-MB-231) carcinoma tumors with high efficiency (Fig. 2E), 
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suggesting that Mek and PI3K inhibitor–loaded LbL nanoparticles may be effective in 
treating solid tumors in vivo.
We next investigated LbL nanoparticle–mediated horizontal blockade in mice bearing 
subcutaneous MDA-MB-231 tumor xenografts. Western blot analyses from excised tumor 
lysates indicated a significant reduction in downstream signaling of both pathways 24 hours 
following intravenous administration of the targeted nanoparticles (1 mg/kg AZD6244, 3.7 
mg/kg PX-866, Fig. 3A). Phosphorylation of Erk1/2 and Akt were reduced 3.9- and 9.4-fold, 
respectively, following nanoparticle delivery (Fig. 3B). These effects were corroborated by 
immunohistochemical staining, which also correlated with an increase in apoptotic tumor 
cell killing as indicated by increased staining of cleaved caspase-3 (Fig. 3C).
We further investigated effects from LbL nanoparticle tumor targeting on subsequent 
treatment outcomes from horizontal blockade. Mice treated with tumor-targeted LbL 
nanoparticles exhibited significant disease stabilization (16% ± 11% at day 30) following 
intravenous administration of dual drug-containing particles (Fig. 3D). In contrast, mice 
similarly treated with nontargeting control LbL nanoparticles of comparable size and charge 
(Fig. 3D, “untargeted”) exhibited slowed, but progressive disease (80% ± 50% at day 30). 
Interestingly, tumor-targeted vehicle LbL nanoparticles that did not contain drug elicited a 
small but significant (1.6 ± 0.8-fold) decrease in tumor size relative to untreated controls, a 
response which may be attributable to antiproliferative interactions between high molecular 
mass hyaluronan (58) on the LbL particle surface and CD44 receptors expressed highly on 
triple-negative breast cell lines including MDA-MB-231 (24). Equivalent doses of the free 
drugs were poorly tolerated, resulting in rapid morbidity and mortality in tumor-bearing 
mice. Histologic analysis of tissue sections from vital organs (24 hours) indicated significant 
damage in tissues surrounding the hepatic central vein and bile ducts (Fig. 4A and B), 
including fragmented nuclei and erythrocyte extravasation following administration of the 
free drug combination. In contrast, mice that received drug-containing LbL nanoparticles—
both targeted and untargeted—exhibited no significant histopathologic differences with 
controls or vehicles alone. Interestingly, immunocompetent mice receiving a half-equivalent 
dose of the free drug combination exhibited a significant decrease in serum albumin (1.5 ± 
0.3 g/dL) and a 40 ± 20-fold elevation in serum blood urea nitrogen:creatinine (BUN:Cr) 
levels (Fig. 4C and D), indicative of impaired hepatic and renal function, respectively, 
whereas mice receiving a full dose of the tumor-targeted LbL nanoparticle formulation 
exhibited no significant changes in serum albumin, BUN, or Cr. Collectively, these data 
indicate that LbL nanoparticle encapsulation can direct tissue disposition of drug 
combinations in a manner that enhances their therapeutic index—in addition to drug 
synergy. Biochemical and histopathologic damage observed here from the free drug 
combination is consistent with a previous phase I clinical trial investigating horizontal 
blockade in patients with refractory solid tumors that reported dose-limiting hepatic toxicity 
as a common grade >3 adverse event (45), consistent with the hepatic damage we observed 
in this murine model. Interestingly, mice receiving tumor-targeted LbL nanoparticles 
exhibited no significant change in body condition and only transient changes in serum 
cytokine levels (Supplementary Fig. S2). These findings may be attributable to improved 
tissue distribution profiles of these novel drug carriers, where we previously observed 4-fold 
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improved tumor targeting (ca. 6%ID) and 2-fold decreased liver accumulation in tumor-
bearing and immunocompetent mice, respectively, compared with nontargeting LbL 
nanoparticle architectures (24). Together, these findings suggest that LbL nanoparticle-
mediated horizontal blockade could be impactful in improving treatment outcomes in solid 
tumors driven by MAPK or PI3K axis signaling.
Discussion
Simultaneous blockade of MAPK and PI3K pathway signaling has been shown to 
synergistically kill a variety of solid tumors in vivo and abrogate resistance-associated 
signaling (33, 42, 44, 55). Shimizu and colleagues, in a retrospective phase I clinical study 
of 236 patients with advanced solid tumors receiving small-molecule MAPK or PI3K 
pathway inhibitors, alone or in combination, found that combined blockade elicited 
favorable treatment response in the advanced disease population. This favorable response, 
however, came at the expense of greater toxicity, resulting in a 2.0-fold increased prevalence 
of dose-limiting toxicity and a 3.0-fold increased prevalence of drug-related grade >3 
adverse events (45). Nanoscale drug formulations such as Abraxane and Doxil can enhance 
therapeutic index in patients (5) and improve treatments outcomes in combination delivery 
approaches (6, 9, 12, 14). Previously, we demonstrated that an emerging class of nanoscale 
drug carrier, LbL nanoparticles, could improve tumor accumulation 4.0-fold and decrease 
liver accumulation 2.0-fold (24). We hypothesized that the enhanced tissue disposition 
profiles afforded by these novel drug carriers could improve tumor cell killing from dual 
MAPK/PI3K inhibition while reducing drug-related hepatotoxicity such as that indicated by 
increased transaminase levels reported by Shimizu and colleagues. An improved safety 
profile could potentially augment tolerable dosing levels in patients and further improve 
response rates to dual MAPK/PI3K pathway inhibition in the clinic.
LbL nanoparticles containing AZD6244 (selumetinib), an allosteric inhibitor of Mek1/2, and 
PX-866, a covalent inhibitor of PI3K, were 160 ± 20 nm in hydrodynamic diameter, well 
below the size-dependent splenic clearance threshold, and negative in surface charge (−40 ± 
1 mV) to prevent nonspecific cell surface interactions. In previous studies, we found that 
these architectures could circulate for long periods following i.v. bolus injection (elimination 
half-life ∼ 28 hours; ref. 8) target tumors with high efficiency and decrease liver-specific 
accumulation (24). In vitro, these nanoscale formulations entered cells through various ATP-
dependent processes (excluding caveolin-dependent entry), simultaneously blocked MAPK 
and PI3K pathway activation, and exhibited synergistic cell killing in excess of the additive 
Bliss expectation. Interestingly, we found that drug synergy was further enhanced following 
nanoscale encapsulation, a factor that could also further improve the therapeutic index of 
dual MAPK/PI3K blockade in the clinic. Consistent with patient responders in Shimizu and 
colleagues harboring co-activation of both MAPK and PI3K pathway signaling, we 
observed synergistic cell killing in basal-like MDA-MB-231 breast cells which harbor an 
activating mutation in KRAS (G12V), high levels of EGFR protein, and PTEN-dependent 
survival following MEK inhibition (55). We further observed drug synergy in KP7B cells 
derived from an autochthonous mouse model of non-small cell lung cancer which host an 
activating mutation in KRAS (G12D) but not in OVCAR3 epithelial ovarian cancer cells, 
which lack any predicating mutations on either axis (PI3KCA, PTEN, KRAS, and BRAF).
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As a proof-of-concept, we investigated tumor remediation in vivo using a subcutaneous 
MDA-MB-231 xenograft mouse model. Following a single i.v. bolus injection, we observed 
significant disease stabilization from our tumor-targeting nanoscale drug formulation but 
progressive disease in our nontargeting control. This response was accompanied by a 
reduction in tumor-specific phosphorylation of the terminal kinases Erk and Akt and an 
increase in apoptosis as histologically measured by cleaved caspase-3 staining. Interestingly, 
combination therapy with the free drugs was lethal at equivalent dosing and, at sublethal 
dosing levels, resulted in acute hepatic and renal dysfunction as measured by decreased 
serum albumin and elevated BUN:Cr levels, as well as gross histopathologic liver damage at 
the full equivalent dose. These findings are consistent with dose-limiting hepatic toxicity 
reported in phase I trial patients receiving dual MAPK/PI3K blockade therapy (45). These 
nanoscale formulations were well-tolerated in tumor-bearing mice and elicited in no acute 
serum cytokine upregulation following systemic administration in immunocompetent mice, 
as well as no significant changes in hepatic or renal function as measured from serum blood 
chemistry and histopathologic analysis of vital organs. Studies are currently under way to 
identify and profile surviving cell sub-populations, optimize dosing regimens, and 
investigate therapeutic response in advanced tumor models. While murine xenografts exhibit 
notable functional and pathologic differences with human breast carcinomas (e.g., stromal 
compaction, labeling index, and vascularity) these results are particularly promising in the 
context of prior work investigating related LbL nanoparticle architectures that demonstrate 
the ability to target and treat tumors in other sites including orthotopic mammary fat pad 
(59) and autochthonous lung tumor models (unpublished data). Although here we found 
these particles capable of rapid diffusion throughout tumor spheroid models, efficient 
intratumoral distribution and the capacity to target poorly vascularlized tumors remains a 
key challenge for these and other emerging classes of nanoscale drug carriers. Efforts to 
further engineer modular LbL nanoparticle delivery platforms that improve therapeutic 
safety, potency, and durability are currently under way.
In summary, here we developed a tumor-targeting nanoscale drug formulation based on LbL 
self-assembly that horizontally blocks MAPK and PI3K signaling in vitro and in vivo, 
selectively inhibiting disease progression in tumor-bearing mice. These self-assembled drug 
carriers co-delivered small-molecule inhibitors of MEK and PI3K with vastly differing 
physiochemical properties and enhanced synergistic cell killing 2.6-fold following 
encapsulation. Following systemic administration in breast tumor xenograft–bearing mice, 
we observed a 3.9- and 9.4-fold reduction in tumor-specific MAPK and PI3K pathway 
signaling, respectively, accompanied by tumor apoptosis and disease stabilization in the 
absence of dose-limiting hepatotoxic effects observed from the free drug combination. Mice 
receiving untargeted, but dual drug– loaded nanoscale formulations, exhibited progressive 
disease. Tumor-targeting nanoscale drug formulations could provide a more safe and 
effective means to synergistically block MAPK and PI3K in the clinic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
The MAPK and PI3K cell signaling pathways encompass numerous clinically approved 
drug targets, and recent evidence suggests that cross-talk/feedback between these 
pathways is critical for initiation and maintenance of various solid tumors, as well as 
resistance to targeted therapies. Simultaneous blockade of these two signaling axes is a 
promising therapeutic strategy; however, rational combinations approaches with small-
molecule inhibitors are poorly tolerated in patients. In this work, we develop a tumor-
targeting nanoscale drug formulation based on layer-by-layer (LbL) self-assembly that 
horizontally blocks MAPK and PI3K signaling in vitro and in vivo, selectively inhibiting 
disease progression in tumor-bearing mice. These self-assembled drug carriers co-
delivered synergistic drug compounds with vastly differing physiochemical properties, in 
a manner that pre-empted adaptive resistance and diminished toxic effects of the free 
drug combination. This approach could provide a more safe and effective means to 
synergistically block MAPK and PI3K in the clinic.
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Figure 1. 
An engineered LbL nanoparticle for tumor-targeted horizontal blockade of MAPK and PI3K 
signaling. A, schematic illustrating combined blockade of MEK (AZD6244) and PI3K 
(PX-866) via multimodal tumor-targeting LbL nanoparticles. B, cryogenic transmission 
electron microscopy (cryo-TEM) of cationic, drug-encapsulating liposomal cores (left) and 
tumor-targeting, LbL-coated liposomes (right). Size evolution (C) and corresponding surface 
charge shift (D) during the LbL assembly process as measured by dynamic light scattering 
and laser Doppler electrophoresis (zeta potential analysis), respectively. E, in vitro delivery 
and penetration of tumor-targeting LbL nanoparticles (green) into Hep G2 tumor spheroids 
(actin, red) as measured by confocal fluorescence microscopy. F, mechanistic analysis of 
LbL nanoparticle cell uptake (1 hour) as measured by flow cytometry of particle-treated 
MDA-MB-231 cell monolayers pretreated with inhibitors of various endocytotic pathways 
indicated. Polydispersity index (PDI) in (C) is reported in parentheses. Error represents (C 
and D) SD of 3 technical and (F) SEM of 3 biological replicates. *, P < 0.05; **, P < 0.01; 
***, P < 0.001.
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Figure 2. 
Rational drug combination nanomedicines against MAPK/PI3K signaling synergistically kill 
tumor cell lines in vitro and target solid tumors in vivo. A, drug interaction matrix plotting 
cell killing observed in excess of the additive Bliss expectation between MEK and PI3K 
inhibition in triple-negative breast and RAS-mutant non-small cell lung carcinoma (MDA-
MB-231, KP7B; 0.05-50 μmol/L, 48 hours). B, LbL nanoparticle encapsulation augments 
drug synergy in vitro and (C) horizontally blocks MAPK and PI3K signaling as measured by 
phospho-Erk1/2 and phospho-Akt cell staining, respectively. D, at early time points (10-
minute serum stimulation), LbL nanoparticle-encapsulated drugs deplete relative pAkt more 
completely than the equivalent free drug combination. E, in vivo 3D fluorescence 
tomography of LbL nanoparticles indicates high colocalization with subcutaneous MDA-
MB-231 tumor xenografts following systemic administration. B, 1.1 μmol/L AZD6244 and 
3.5 μmol/L PX-866, 48 hours. C, 50 nmol/L AZD6244, 160 nmol/L PX-866, 2 hours, PBS; 
serum stimulation, 1 hour. D, 0.3 μmol/L AZD6244, 1 μmol/L PX-866, 1 hour; serum 
stimulation, 10 minutes. E, obtained with structured illumination of the lower abdomen (24 
hours; 8.3 × 1012 NP/kg, 5% glucose; 715/760 ex/em). Error bars represent (B) SD of 4 
technical and (C) SEM of 3 biological replicates.
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Figure 3. 
Tumor-targeting LbL nanoparticles horizontally block tumor-specific MAPK/PI3K 
signaling and induce disease stabilization in vivo. A, combined signal blockade as measured 
by decreased phosphorylation of Akt and Erk1/2 as measured by Western blotting and (B) 
densitometry from tumor lysates of untreated and nanoparticle-treated mice bearing 
subcutaneous MDA-MB-231 xenografts 24 hours following i.v. administration of LbL 
nanoparticles. C, histologic analysis of corresponding tumor sections indicating decreased 
phospho-Erk1/2 and phospho-Akt staining, as well as increased cell death as measured by 
cleaved caspase-3 (CC3). D, in vivo treatment response following i.v. nanoparticle 
administration on days 0 and 5 (n = 5). Lanes 3 and 4 are technical replicates of lanes 1 and 
2 in A. Scale bar in (C) is 200 mm. Error bars represent (B) SD of 2 to 4 technical and (D) 
SEM of 5 biological replicates. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 4. 
LbL nanoparticles improve the therapeutic index of dual MAPK/PI3K pathway inhibition. 
A, hepatic degeneration score as assessed from hematoxylin and eosin (H&E)-stained liver 
sections from immunocompetent BALB/c mice 24 hours following combination drug 
administration as targeted and untargeted LbL nanoparticle formulations, as well as their 
respective vehicles, in comparison to a lethal equivalent dose of the free drug combination. 
B, H&E-stained liver sections from MDA-MB-231 tumor xenograft-bearing NCR nude 
mice (n = 5) 24 hours following administration of free AZD6244 and free PX-866 (1 mg/kg 
AZD6244, 3.7 mg/kg PX-866 o.g.). Arrowheads indicate damage to tissues surrounding the 
hepatic central vein and bile ducts including fragmented nuclei and extravasated 
erythrocytes. C and D, nanoparticle-rescued hepatic and renal function as measured from 
serum albumin, BUN, and creatinine levels 24 hours following combination drug 
administration as an LbL nanoparticle formulation and as a sublethal (0.5x) free drug 
combination in immunocompetent BALB/c mice. Shaded area in C and D denotes normal 
murine reference ranges (95% CI) from ref. 60. Error represents SEM of 2 to 5 biological 
replicates. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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